Home LiteratureArticle Details
PMID: 6537916 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial

Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy.

European journal of cancer & clinical oncology ·Vol. 20 ·No. 1 ·1984-01-00 ·Pages 55-60

Sculier JP, Weerts D, Klastersky J

Abstract

We reviewed the causes of death of 55 granulocytopenic patients who received empiric antibiotic treatment for fever according to an EORTC cooperative protocol; 53 presented cancer and 2 aplastic anemia. Among the 55 patients, 19 (35%) deaths were attributed to infection: 16 to bacterial and 3 to fungal infections. Among the patients with bacterial infections, 12 died from septic shock, 3 from pneumonia and 1 from Pseudomonas aeruginosa meningitis. The most frequent non-infectious causes of death were the cancer progression (18%) and hemorrhagic complications (27%), most often cerebromeningeal in relationship to thrombocytopenia. A large number of the patients who died from infection (78%) and hemorrhage (74%) had advanced cancer with poor chances to respond to anticancer therapy.

MeSH Terms
Adult Aged Agranulocytosis/complications,mortality Anti-Bacterial Agents/therapeutic use Bacterial Infections/complications,drug therapy,mortality Female Fever/complications,drug therapy Humans Middle Aged Neoplasms/complications,mortality Shock, Septic/mortality
Chemicals
Anti-Bacterial Agents
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Sculier J P
Weerts D
Klastersky J
Article Info
Journal
European journal of cancer & clinical oncology
Abbr.
Eur J Cancer Clin Oncol
ISSN
0277-5379
Published
1984-01-00
Pages
55-60
Language
English
Region
England
NLM ID
8112045
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com